Radiopharmaceuticals for diagnosis and treatment
In this grant period we have continued our efforts in the areas of PE basic radiochemistry, radiopharmaceutical synthesis, and preclinical radiopharmaceutical evaluation. A new synthetic sequence, consisting, of no-carrier-added fluorine-18 labeling of substituted benzaldehydes followed by reductive decarbonylation, has been developed. This new methodology can be applied to the fluorine-18 labeling of a wide variety of drugs not previously accessible through existing fluorine-18 labeling methods. Following up on a literature report that the ability to radiolabel aromatic rings can be predicted by {sup 13}C-NMR chemical shifts, we have examined the generality of this correlation in aromatic rings bearing a variety of substituents. Although the original correlation holds for nitro substituted anisaldehydes, it cannot be extended to other rings substitution patterns. We have examined the relationship of in vivo localization of various fluorine-18 labeled dopamine uptake inhibitors to their in vitro binding affinities and lipophilicities. We have found that remarkably small decreases in binding affinity result in dramatic losses of in vivo binding to the desired high affinity binding sites. In order to probe the effects of endogenous neurotransmitter on the in vivo binding of radiolabeled dopamine uptake inhibitors, we have examined the in vivo regional localization of (18{sub F}) GBR 13119 after acute and chronic drug treatments which alter the endogenous levels of dopamine. We have found that acute changes in dopamine levels do not affect the binding of this radioligand, but chronic depletion of neurotransmitter results in down-regulation of the in vivo binding sites. 16 refs., 2 figs., 1 tab.
- Research Organization:
- Michigan Univ., Ann Arbor, MI (United States)
- Sponsoring Organization:
- DOE; USDOE, Washington, DC (United States)
- DOE Contract Number:
- FG02-88ER60639
- OSTI ID:
- 6262745
- Report Number(s):
- DOE/ER/60639-4; ON: DE92004065
- Country of Publication:
- United States
- Language:
- English
Similar Records
Radiopharmaceuticals for diagnosis and treatment. Progress report
Radiopharmaceuticals for diagnosis and treatment
Related Subjects
400703 -- Radiochemistry & Nuclear Chemistry-- Radioisotope Production
550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
AMINES
AROMATICS
AUTONOMIC NERVOUS SYSTEM AGENTS
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
CARDIOTONICS
CARDIOVASCULAR AGENTS
CHEMICAL PREPARATION
COMPUTERIZED TOMOGRAPHY
DIAGNOSTIC TECHNIQUES
DOCUMENT TYPES
DOPAMINE
DRUGS
EMISSION COMPUTED TOMOGRAPHY
FLUORINE 18
FLUORINE ISOTOPES
HOURS LIVING RADIOISOTOPES
HYDROXY COMPOUNDS
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
LIGANDS
LIGHT NUCLEI
MEDICINE
MEMBRANE PROTEINS
NANOSEC LIVING RADIOISOTOPES
NEUROREGULATORS
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANIC COMPOUNDS
PHENOLS
POLYPHENOLS
POSITRON COMPUTED TOMOGRAPHY
PROGRESS REPORT
PROTEINS
RADIOISOTOPES
RADIOPHARMACEUTICALS
REACTION INTERMEDIATES
RECEPTORS
STRUCTURE-ACTIVITY RELATIONSHIPS
SYMPATHOMIMETICS
SYNTHESIS
TOMOGRAPHY